The Expanding Clinical Application of TRK Inhibitors in Cancer Care: A Podcast Series

In this podcast series with downloadable slidesets experts discuss the importance of testing for NTRK fusions the use of TRK inhibitors for solid cancers and optimal treatment strategies for patients with acquired resistance to first-generation TRK inhibitors.

Share

Program Content

Activities

<i>NTRK</i> Testing Rationale
Rationale for NTRK Testing in Patients With Cancer
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: October 08, 2021

Expires: October 07, 2022

<i>Podcast Pearls</i>: <i>NTRK</i> Testing Rationale
Podcast Pearls
Rationale for NTRK Testing in Patients With Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 08, 2021

Expires: October 07, 2022

1st-Gen TRK Inhibitors
First-Generation TRK Inhibitors: Clinical Evidence and Indications
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: October 15, 2021

Expires: October 14, 2022

<i>Podcast Pearls</i>: 1st-Gen TRK Inhibitors
Podcast Pearls
First-Generation TRK Inhibitors: Clinical Evidence and Indications
Podcast Episodes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 15, 2021

Expires: October 14, 2022

2nd-Gen TRK Inhibitors
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: November 09, 2021

Expires: November 08, 2022

<i>Podcast Pearls</i>: 2nd-Gen TRK Inhibitors
Podcast Pearls
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors
Podcast Episodes
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 09, 2021

Expires: November 08, 2022

Faculty

cover img faculity

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Alexander E Drilon, MD

Chief, Early Drug Development Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma